Ergot pharmacology and alternative delivery systems for ergotamine derivatives.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 1557192.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Dihydroergotamine mesylate (DHE) has been used in migraine therapy since the 1940s. Renewed interest in its use has been kindled by research in receptor pharmacology and by efficacy of DHE-45 in breaking the cycle of chronic daily headache. Nasal and oral routes of administration may widen the applicability of DHE.
Medical subject headings
- Dihydroergotamine
- Migraine Disorders